The FDA-Approved Anti-Asthma Medicine Ciclesonide Inhibits Lung Cancer Stem Cells through Hedgehog Signaling-Mediated SOX2 Regulation

The FDA-Approved Anti-Asthma Medicine Ciclesonide Inhibits Lung Cancer Stem Cells through Hedgehog Signaling-Mediated SOX2 Regulation

Ciclesonide is an FDA-approved glucocorticoid (GC) used to treat asthma and allergic rhinitis. However, its effects on cancer and cancer stem cells (CSCs) are unknown. Our study focuses on investigating the inhibitory effect of ciclesonide on lung cancer and CSCs and its underlying mechanism. In thi...

Full description

Bibliographic Details
Main Authors: Hack Sun Choi, Su-Lim Kim, Ji-Hyang Kim, Dong-Sun Lee
Format: Article
Language:English
Published: MDPI AG 2020-02-01
Series:International Journal of Molecular Sciences
Subjects:
lung cancer stem cells
ciclesonide
hedgehog signaling
gl1
gl2
smo
Online Access:https://www.mdpi.com/1422-0067/21/3/1014

Internet

https://www.mdpi.com/1422-0067/21/3/1014

Similar Items